RxDoctor Payments Data

Faheemullah Beg, MD

Cardiovascular Disease · Conway, ARNPI 1801209614

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,973 of the $9,623 with a category attached, or 82.8%. 43 manufacturers reported payments, led by Boston Scientific at 24.0% of the total. Reporting peaked in 2022 at $2,003 and has fallen 56.0% since, to $882 in 2025.

$9,623in general payments, 2019–2025

Across 371 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Pfizer$1K
  • Abbott$856
  • Biosense Webster, Inc.$786
  • Novartis$572
  • Medtronic$460
  • plus $4K from 37 others

What the payments were for

  • Grants$1,60517%
  • Food & beverage$7,97383%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,623 in reported general payments places this provider in the 75th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$146,751
Medicare patients
975
Services billed
2,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$66,549
JardianceEmpagliflozin38$34,957
XareltoRivaroxaban22$18,811
Prasugrel Hcl27$3,449
Amiodarone Hcl41$1,699
Metoprolol Succinate145$1,227
Rosuvastatin Calcium116$906
Amlodipine Besylate158$755
Ezetimibe47$683
ClopidogrelClopidogrel Bisulfate67$617
Atorvastatin Calcium97$601
Torsemide32$469
Losartan Potassium54$417
Isosorbide Mononitrate ErIsosorbide Mononitrate57$406
Carvedilol83$368

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,008$66,54990 claims
Boehringer IngelheimJardiance$292$34,95738 claims
Johnson & JohnsonXarelto$324$18,81122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →